Effectiveness of a Schema Therapy on Anxiety in Patients With Multiple Sclerosis
Primary Purpose
Anxiety
Status
Unknown status
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
schema therapy
Sponsored by
About this trial
This is an interventional supportive care trial for Anxiety focused on measuring anxiety, multiple sclerosis, schema therapy
Eligibility Criteria
Inclusion Criteria:
- subject has relapsing remitting MS
- anxiety (score >26 at the BAI scale)
- history of psychotic disorders
- history of cognitive deficiency
- use anti-depressant in the past 3 months
- history of relapse in the past 3 month
- expanded Disability Status Scale score less than 6
- ability reading and writing Persian
- Non hospitalized
Exclusion Criteria:
- history of psychotic disorders
- history of cognitive deficiency
- use anti-depressant in the past 3 months
- history of relapse in the past 3 month
Sites / Locations
- university Paris Nanterre
Arms of the Study
Arm 1
Arm 2
Arm Type
No Intervention
Experimental
Arm Label
control group
experimental group
Arm Description
no intervention
schema therapy
Outcomes
Primary Outcome Measures
changes Anxiety in patient with MS,Beck Anxiety Inventory (BAI)
Beck Anxiety Inventory (BAI),self-reported questionnaire of anxiety,.21-question multiple- choice each answer being scored on a scale value of 0 (not at all) to 3 (severely),Higher total scores indicate more severe anxiety symptoms . score between 0-63
changes in level of cortisol
cortisol measure by Immunoassay by cortisol saliva ELISA, DiaMetra ( kit),adult morning peak :3-10 ,higher values represent more anxiety
Secondary Outcome Measures
changes in depression,Beck Depression Inventory (BDI)
Beck Depression Inventory (BDI)- self report questionnaires,21-question multiple-choice,each answer being scored on a scale value of 0 (not at all) to 3 (severely),total scores indicate more severe depression symptoms . score between 0-63
changes quality of life.Multiple sclerosis impact scale - 29 items(MSIS29)
Multiple sclerosis impact scale - 29 items.self -reported questionnaires (MSIS29):29-item self-report measure with 20 items associated with a physical scale and 9 items with a psychological scale,Each of the two scales are scored by summing the responses across items, then converting to a 0-100 scale where 100 indicates greater impact of disease on daily function (worse health).
changes in quality of sleep.Pittsburgh Sleep Quality Index (PSQI)
Pittsburgh Sleep Quality Index (PSQI) : self-report questionnaire that assesses sleep quality over a 1-month time intervalself-report questionnaire that assesses sleep quality over a 1-month time interval. The measure consists of 19 individual items,Each item is weighted on a 0-3 interval scale The global PSQI score is then calculated by totaling the seven component scores, providing an overall score ranging from 0 to 21, where lower scores denote a healthier sleep quality..
changes in fatigue.Fatigue Severity Scale (FSS)
Fatigue Severity Scale (FSS). self -reported questionnaires The FSS questionnaire contains nine statements that attempt to explore severity of fatigue symptoms.each item being scored on a scale value of 1 to 7. score between 9-63.higher the score indicate greater fatigue
Full Information
NCT ID
NCT04030819
First Posted
July 11, 2019
Last Updated
July 27, 2019
Sponsor
Paris Nanterre University
Collaborators
Isfahan University of Medical Sciences
1. Study Identification
Unique Protocol Identification Number
NCT04030819
Brief Title
Effectiveness of a Schema Therapy on Anxiety in Patients With Multiple Sclerosis
Official Title
Effectiveness of a Schema Therapy on Anxiety in Patients With Multiple Sclerosis .a Randomized Control Study in 106Persian Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
Study Type
Interventional
2. Study Status
Record Verification Date
July 2019
Overall Recruitment Status
Unknown status
Study Start Date
December 20, 2018 (Actual)
Primary Completion Date
June 18, 2019 (Actual)
Study Completion Date
December 15, 2019 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Paris Nanterre University
Collaborators
Isfahan University of Medical Sciences
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
It is a multicentric randomized and controlled study comparing a Scheme therapy program versus local practice in RRMS patients with anxiety. Patients will assist to twenty once-weekly group sessions with a 6-month follow up after the end of the programme. The main criteria is the impact of schema therapy on anxiety evaluated by the questionnaires at the end of the program and at the end of the 6-month follow-up.
Detailed Description
A parallel arm randomized controlled trial comparing a group receiving Scheme Therapy plus current usual practice versus a group receiving current local practice only. The trial will take place in KASHANI Hospital (in Isfahan).Recruitment of the participants will be identified and recruited by the neurologists of the hospitals who take part in the programme, when they come for a medical examination.
After giving their informed consent, the patients will be entered onto the trial database and randomized to either the schema therapy or control using software allocated The intervention is the schema therapy focuses on the management of anxiety and is based on self-efficacy, self-management . It consists of 20 once-weekly sessions of 90 minutes (with a 15 Min break), with homework activities between the sessions. It is designed for groups of 8 people and will be delivered by two psychologists. The programme is standardized: Power Points presentations support each session and a detailed therapist manual and companion patient workbook accompany the programme.
For the ST group an evaluation will be administered pretest and post-test six months after the end of the schema therapy programme and at the same times for those in the control group. Socio-demographic and medical data, age, sex, level of education, marital status, number of children and professional status; date of diagnosis, disease type, level of disability (EDSS, Kurtzke, 1983) and information on relapses and treatments, are evaluated. The main criteria is the impact of schema therapy on anxiety evaluated by the BAI (beck anxiety inventory ) and level of cortisol at 6 month after the start program . Secondary criteria are: impact on the psychological dimensions assessed by Hospital Anxiety and Depression Scale (HADS), intensity of fatigue assessed by Fatigue Severity Scale (FSS), sleep quality evaluated by the Pittsburgh Sleep Quality Index(PSQI) depression by BDI (beck depression inventory ) and quality of life evaluated by (Multiple sclerosis impact scale) MSIS29.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Anxiety
Keywords
anxiety, multiple sclerosis, schema therapy
7. Study Design
Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
106 (Actual)
8. Arms, Groups, and Interventions
Arm Title
control group
Arm Type
No Intervention
Arm Description
no intervention
Arm Title
experimental group
Arm Type
Experimental
Arm Description
schema therapy
Intervention Type
Behavioral
Intervention Name(s)
schema therapy
Intervention Description
The intervention is the schema therapy focuses on the management of anxiety and is based on self-efficacy, self-management . It consists of 20 once-weekly sessions of 90 minutes (with a 15 Min break), with homework activities between the sessions
Primary Outcome Measure Information:
Title
changes Anxiety in patient with MS,Beck Anxiety Inventory (BAI)
Description
Beck Anxiety Inventory (BAI),self-reported questionnaire of anxiety,.21-question multiple- choice each answer being scored on a scale value of 0 (not at all) to 3 (severely),Higher total scores indicate more severe anxiety symptoms . score between 0-63
Time Frame
Change measures in 0,6,12 month
Title
changes in level of cortisol
Description
cortisol measure by Immunoassay by cortisol saliva ELISA, DiaMetra ( kit),adult morning peak :3-10 ,higher values represent more anxiety
Time Frame
Change measures in 0,6,12 month
Secondary Outcome Measure Information:
Title
changes in depression,Beck Depression Inventory (BDI)
Description
Beck Depression Inventory (BDI)- self report questionnaires,21-question multiple-choice,each answer being scored on a scale value of 0 (not at all) to 3 (severely),total scores indicate more severe depression symptoms . score between 0-63
Time Frame
Change measures in 0,6,12 month
Title
changes quality of life.Multiple sclerosis impact scale - 29 items(MSIS29)
Description
Multiple sclerosis impact scale - 29 items.self -reported questionnaires (MSIS29):29-item self-report measure with 20 items associated with a physical scale and 9 items with a psychological scale,Each of the two scales are scored by summing the responses across items, then converting to a 0-100 scale where 100 indicates greater impact of disease on daily function (worse health).
Time Frame
Change measures in 0,6,12 month
Title
changes in quality of sleep.Pittsburgh Sleep Quality Index (PSQI)
Description
Pittsburgh Sleep Quality Index (PSQI) : self-report questionnaire that assesses sleep quality over a 1-month time intervalself-report questionnaire that assesses sleep quality over a 1-month time interval. The measure consists of 19 individual items,Each item is weighted on a 0-3 interval scale The global PSQI score is then calculated by totaling the seven component scores, providing an overall score ranging from 0 to 21, where lower scores denote a healthier sleep quality..
Time Frame
Change measures in 0,6,12 month
Title
changes in fatigue.Fatigue Severity Scale (FSS)
Description
Fatigue Severity Scale (FSS). self -reported questionnaires The FSS questionnaire contains nine statements that attempt to explore severity of fatigue symptoms.each item being scored on a scale value of 1 to 7. score between 9-63.higher the score indicate greater fatigue
Time Frame
Change measures in 0,6,12 month
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
subject has relapsing remitting MS
anxiety (score >26 at the BAI scale)
history of psychotic disorders
history of cognitive deficiency
use anti-depressant in the past 3 months
history of relapse in the past 3 month
expanded Disability Status Scale score less than 6
ability reading and writing Persian
Non hospitalized
Exclusion Criteria:
history of psychotic disorders
history of cognitive deficiency
use anti-depressant in the past 3 months
history of relapse in the past 3 month
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Marie claire GAY, full prof
Organizational Affiliation
university paris Nanterre
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
vahid shaygannejad, professor
Organizational Affiliation
Isfahan university of medical science
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
AZAM Mansourzadeh
Organizational Affiliation
university paris Nanterre
Official's Role
Principal Investigator
Facility Information:
Facility Name
university Paris Nanterre
City
Paris
ZIP/Postal Code
75
Country
France
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Effectiveness of a Schema Therapy on Anxiety in Patients With Multiple Sclerosis
We'll reach out to this number within 24 hrs